IMMUNIQUE is a company specialized in the development of cord blood-derived immune cell therapeutics. Our focus centers on developing regulatory T cell therapeutics to treat intractable diseases including autoimmune diseases and immunodeficiency-related diseases.

The name “IMMUNIQUE” is a portmanteau of words “IMMUNE” and “UNIQUE,” expressing our determination to become a globally unique developer of immune cell therapeutics. The symbolic color purple represents our “Purple Ocean” strategy, with the goal of swiftly transitioning from the globally competitive “Red Ocean” market of cell therapeutics to “Blue Ocean”.

With my 30 years of experience in cord blood-related basic and clinical research as a professor in university hospital, along with the commercialization expertise of our parent company, MEDIPOST, in stem cell therapeutics, IMMUNIQUE is ready to leap forward as a company specialized in immune cell therapeutics. We pledge to enhance our research capabilities and actively engage in business initiatives, with the goal of contributing to the well-being and happiness of humanity.

CEO of IMMUNIQUE, Inc.